APSR2026-966

Yes
Late-Breaking
Submitted
Oral Presentation
AO17-004
 
 
https://storage.unitedwebnetwork.com/files/1285/1243192-46903-APSR2026_966_revised_440475.pptx
Format: PPTX Only
 
Format: PDF Only
07. COPD
15

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Dinh Bui * University of Melbourne Medicine Melbourne Australia
Benjamin Georgi - AstraZeneca Research and Early Development Gothenburg Switzerland
Sabrina Idrose - University of Melbourne Medicine Melbourne Australia
Eleanor Wheeler - AstraZeneca Centre for Genomics Research Cambridge United Kingdom
Coralie Coralie Viollet - AstraZeneca Centre for Genomics Research Cambridge United Kingdom
Jennifer Perret - University of Melbourne Medicine Melbourne Australia
Michael Abramson - University of Melbourne Medicine Melbourne Australia
Erin Oerton - AstraZeneca Centre for Genomics Research Cambridge United Kingdom
Slavé Petrovski - AstraZeneca Centre for Genomics Research Cambridge United Kingdom
Chris Chamberlain - AstraZeneca Translational Science & Experimental Medicine Cambridge United Kingdom
Daniel Muthas - AstraZeneca Research and Early Development Gothenburg Switzerland
Adam Platt - AstraZeneca Translational Science & Experimental Medicine Cambridge United Kingdom
Haydn Walters - University of Melbourne Medicine Melbourne Australia
Glenda Lassi - AstraZeneca Translational Science & Experimental Medicine Cambridge United Kingdom
Shyamali Dharmage - University of Melbourne Medicine Melbourne Australia
Presenting Author Details
Dinh
Bui
dinh.bui@unimelb.edu.au
+61484616813
41-50
Australia
Original Research
Polygenic basis of lifetime lung function trajectories and spirometry patterns in the Tasmanian Longitudinal Health Study
Maximum 25 words
Abstract Content
Identifying lung function trajectories leading to chronic obstructive pulmonary disease (COPD) requires repeated measures from childhood into adulthood. We aimed to determine whether polygenic scores (PGS) could predict these longitudinal lung function trajectories, spirometry patterns, and COPD development.
Using the Tasmanian Longitudinal Health Study, we extracted genomic data from 2,981 participants who were followed serially from ages 7 to 53 years. PGS for FEV1, FVC and FEV1/FVC ratio z-scores were trained on the UK Biobank dataset. Logistic regression tested associations between each PGS and (a) established lung function trajectories (7-53 years); (b) lifetime spirometry patterns of obstruction and restriction (7-53 years); and (c) spirometry-defined COPD at age 53 years.
Low PGSs (below median) for FEV₁, FVC and FEV₁/FVC were associated with increased odds of adverse trajectories characterised by early low, persistently low, or accelerated lung function decline (odds ratios [ORs] 2.07-5.65). Low PGSs were also associated with markedly reduced odds of belonging to the supranormal “persistently high” trajectories (ORs: 0.26-0.45). The associations of PGS with lifetime spirometry patterns, classified as “obstructive only”, “restrictive only” and “mixed”, were generally stronger than those observed for trajectories of individual spirometric indices (FEV1, FEV1/FVC or FVC). The lifetime restrictive-only pattern was predominantly associated with low PGSs for FEV₁ and FVC (OR: 3.04-3.16), while the lifetime obstructive-only pattern and COPD were predominantly associated with low PGS for FEV₁/FVC (OR: 3.33 and 4.42 respectively). Associations between low PGSs for all indices and the “mixed” spirometry pattern were stronger (ORs: 3.41-6.32).
Our findings suggest that lifetime lung function trajectories and COPD are polygenic traits. PGS may have potential utility for early risk stratification, biomarker-guided prevention, drug development and subtyping disease.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
polygenic scores; COPD; lung function trajectories
maximum 3 keywords and no abbreviations, separated by commas
Follow-ups of the Tasmanian Longitudinal Health Study were funded by Australian National Health and Medical Research Council. AstraZeneca funded genetic assays.
288